TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05109689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT-P
Description: ACT-P consists of five modules. The Big Picture sessions are interwoven throughout the 24 sessions to introduce the main concepts of the curriculum, such as values identification and awareness of criminal behaviors. The Emotion Regulation and Cognitive Skills modules focus on awareness of internal experiences; learning new ways to respond to internal experiences; identifying and stepping back from problematic/criminal thoughts and beliefs; awareness of behaviors in service of values versus behaviors in service of control/avoidance; and identifying steps for behavior change. The Behavioral Skills module focuses on practicing prosocial behaviors, such as speaking and listening effectively and conflict resolution. Finally, the Barriers to Change module addresses environmental or life circumstances that can hinder successful behavior change (e.g., toxic masculinity, substance use, and parenting difficulties).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: T4C
Description: T4C is an integrated cognitive behavioral change program authored by Drs. Jack Bush, Barry Glick, and Juliana Taymans under a cooperative agreement with the National Institute of Corrections (NIC). The program is based on the principle that thinking controls how people act, and that to change the way people act, they have to control their thinking. T4C systematically presents the concept that thoughts cause one's behavior, and offenders learn to identify their own thought patterns that lead to risky behavior, and then to replace those maladaptive thoughts with new ones. T4C incorporates research from cognitive restructuring theory, social skills development, and the learning and use of problem solving skills.
Study: NCT05637541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG141
Description: The trial consisted of a low-dose group and a high-dose group, each of which was 50mg bid and 100mg bid for 12 or 24 weeks of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG141
Description: The trial consisted of a low-dose group and a high-dose group, each of which was 50mg bid and 100mg bid for 12 or 24 weeks of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GST-HG141
Description: The trial consisted of a low-dose group and a high-dose group, each of which was 50mg bid and 100mg bid for 12 or 24 weeks of treatment
Study: NCT05347563

Intervention type: PROCEDURE
Intervention: Electrical impedance tomography
Description: All change in ventilator settings (mode, tidal volume or inspiratory pressure, Peep, recruitment...)

Intervention type: PROCEDURE
Intervention: Electrical impedance tomography
Description: All change in ventilator settings (mode, tidal volume or inspiratory pressure, Peep, recruitment...)
Study: NCT05807191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo care based on kangaroo care guide
Description: Under the supervision of the researcher, a kangaroo care practice was applied to premature babies by their mothers based on the kangaroo care guide. This practice took 65 minutes. In addition, before the application, the kangaroo application information was explained to the mothers through a brochure.
Study: NCT05528562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP Rapid Access
Description: 'Rapid PrEP Access' is a low-threshold intervention designed to provide on-site access to HIV self-testing at the Victory Program for persons who use opioids.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV self-testing
Description: After enrollment the research assistant (RA) will provide the participant with a HIV self-test and provide instructions on how to obtain a proper sample for the test. It uses an oral fluid test and yields results within 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dried blood spot testing
Description: HIV Dried blood spot (DBS) testing provides an accurate method of measuring the HIV viral load in comparison to plasma viral load.
Study: NCT06235229

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC012F
Description: GC012F is a BCMA/CD19 dual CAR product
Study: NCT05297292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MW02
Description: MW02 is a recombinant anti-VEGF humanized monoclonal antibody injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MW02
Description: MW02 is a recombinant anti-VEGF humanized monoclonal antibody injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MW02
Description: MW02 is a recombinant anti-VEGF humanized monoclonal antibody injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis
Description: a recombinant anti-VEGF humanized monoclonal antibody injection
Study: NCT06082323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT-002-158/Placebo oral tablet(s)
Description: Single ascending dose escalation and multiple ascending dose escalation study followed by an evaluation of food effects on absorption Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT-002-158/Placebo oral tablet(s)
Description: Single ascending dose escalation and multiple ascending dose escalation study followed by an evaluation of food effects on absorption Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT-002-158/Placebo oral tablet(s)
Description: Single ascending dose escalation and multiple ascending dose escalation study followed by an evaluation of food effects on absorption Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Study: NCT04785950

Intervention type: DRUG
Intervention: Low-dose levonorgestrel intrauterine systems (LNG-IUS)
Description: Any low-dose intrauterine system (IUS) marketed in Spain
Study: NCT05962619

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthrocentesis alone
Description: The procedure is done under general anesthesia. The patient is seated inclined at a 45 degree angle with the head turned to contralateral side. The points of needle insertion on the skin, are as follow: a line is drawn from the middle of the tragus to the outer canthus of the eye. The posterior entrance point is located along the canthotragal line, 10 mm from the middle of the tragus line and 2 mm below, the anterior entrance point is placed 10 mm further forward along the line and 10 mm below it . A needle connected to a 10 ml syringe with the Ringer's lactate solution is then inserted into the superior compartment (posterior point), and solution is injected . Another needle is then inserted into the area of articular eminence to enable the free flow of solution through the superior compartment. During the lavage, the mandible is moved through opening, excursive, and protrusive movements to facilitate lysis of adhesions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthrocentesis with hyaluronic acid injection
Description: in this group Once arthrocentesis is completed, an ampule of sodium HA (Hyalgan 1 ml) is connected to the needle in situ And 0.5 ml injected into the superior joint space. Pressure dressing is placed in site of injection. so We use arthrocentesis hyaluronic acid injection in management of temporomandibular joint dysfunction in the form of anterior disc displacement with reduction
Study: NCT05215470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is called an anti-PD-1 (Programmed Cell Death Ligand 1) or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is called an anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer
Study: NCT06234579

Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsy (tissue or liquid)
Description: At the time of diagnosis, all newly diagnosed ALK+ NSCLC patients eligible for first line treatment with alectinib or brigatinib or lorlatinib will be considered for the study.~In case of progression, a multidisciplinary team (oncologists, interventional pneumologists and radiologists, surgeons) will discuss case-by-case the feasibility to procure an adequate biopsy from progressing lesions. Repeat biopsies will be performed within 2 weeks from multidisciplinary evaluation and before the start of subsequent treatment. If repeat biopsies are not technically or safely feasible or fail to yield sufficient material for genomic analysis, we will collect a whole blood drawn by venepuncture for the analysis of ctDNA.
Study: NCT04884217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pro-ocular™ Topical Gel
Description: Pro-ocular™ Topical Gel 1% is applied dermally to the forehead twice-daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Topical Gel
Description: Placebo is a toopical gel without active ingredient applied dermally to the forehead twice-daily
Study: NCT05336019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes self-management Coaching
Description: A 12-week Diabetes self-management coaching program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Assigned to 12 weeks of usual care which includes a physical examination, history taking,, medication refill, lab investigation, and health education
Study: NCT05794672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elarekibep
Description: Subjects will receive single or multiple inhaled doses A, B or C, or single IV dose D of elarekibep.
Study: NCT06204913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group
Study: NCT05794672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elarekibep
Description: Subjects will receive single or multiple inhaled doses A, B or C, or single IV dose D of elarekibep.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive single or multiple inhaled doses A, B or C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive single or multiple inhaled doses A, B or C.
Study: NCT06338813

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital Manometry
Description: The Compass Lumbar Puncture Pressure Transducer (Mirador Biomedical, Seattle, WA, USA) was used as a digital manometer. After the bladder was completely emptied, the catheter was clamped again. 25 cc of sterile saline was injected into the bladder through the urine sample port. The digital manometer was connected to the urine sample port. The IAP value in cmH2O on the digital screen of the device was noted.
Study: NCT05402111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: SEP-363856 will be supplied by 25 mg and 50 mg tablets. Multiple tablets may be required to achieve a single dose.
Study: NCT05507567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neumifil
Description: Liquid for intranasal spray administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neumifil
Description: Liquid for intranasal spray administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Liquid for intranasal spray administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid for intranasal spray administration
Study: NCT05849675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitolisant 17.8 MG [Wakix]
Description: Single dose pitoliosant (36mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose placebo
Study: NCT06510803

Intervention type: DRUG
Intervention: The case intervention is the sevoflurane concentrations with the Drager Apollo workstation
Description: The increases in the sevoflurane concentrations during induction of anesthesia with the Drager Apollo compared with the GE Ohmeda workstations
Study: NCT06305299

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iC9-CAR.B7-H3 T cells
Description: iC9-CAR.B7-H3 T cells will then be administered intraperitoneally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cyclophosphamide 300 mg/m2 IV will be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: fludarabine 30 mg/m2 IV will be given.
Study: NCT06410352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide, Empagliflozin
Description: subcutaneous Semaglutide (GLP-1RA) 1 mg once a 7 day with oral Empagliflozin (SGLT-2i) 25 mg once a day

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minigastric bypass
Description: Endovideososcopic techniques with the intraperitoneal using of synthetic/biological materials. MGB is performed to reduce the absorption surface of the gastrointestinal tract by shunting the greater part of the stomach, the duodenum and the initial section of the small intestine, which reduces the absorption of food and leads to a decrease in the production of gastrointestinal hormones.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Analimentary detoxication
Description: very-low-calorie-restriction diet ('Analimentary-detoxication') including \<100 kcal/day with fat-free vegetables (tomato/cucumber) and salt intake (5-6 g/day), optimum physical activity, and sexual self-restraint.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ramadan fast's weight loss
Description: The participants adhered to fasting on RF season. They strictly adhered to two principles of nutrition during RF: 1) no blood, no smell of fat which means don't eat meat and don't eat fatty foods; 2) the 'Sehri time' (a meal eaten before dawn) included just 1.5-2.0 glass of water and fruits of 80-100 gr (apple, dates, and persimmon). Indeed, the patients followed a diet in which they ate one meal a day - participants have a meal during 'Iftar time' (a meal eaten after sunset).
Study: NCT06225518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized physical activity management system
Description: Participants will be provided with personalized exercise recommendations determined by a decision system by public health nursing and physiotherapy and rehabilitation experts via the mobile application. Targets will be determined for participants based on their completion of physical activity recommendations every day and every week in the mobile application. The initial program will be individually created based on the initial data collected and each participant's lifestyle, physical activity level and barriers to physical activity. Then, depending on the participants' ability to achieve their goals, the duration and intensity of the suggestions given will be individualized to a level that the person can complete.
Study: NCT05508984

Intervention type: DEVICE
Intervention: Amma Cooling Caps
Description: Once enrolled, subjects will be provided the Amma device by the clinic on days of chemotherapy treatment, and upon completion of treatment it will be returned to the clinic for safekeeping. Upon completion of chemotherapy, anywhere from 3-6 weeks following treatment, subjects will repeat the questionnaires and their hair will be photographed again.~The overall duration of the study for subjects will be anywhere from 4 months to 8 months, depending on the duration of their chemotherapy regimen.
Study: NCT05503095

Intervention type: GENETIC
Intervention: Genetic analysis for PCSK9 polymorphisms
Description: Determination of PCSK9 gene polymorphism and serum PCSK9 concentration

Intervention type: GENETIC
Intervention: Genetic analysis for PCSK9 polymorphisms
Description: Determination of PCSK9 gene polymorphism and serum PCSK9 concentration
Study: NCT05607173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole (HOE239)
Description: Route of administration: oral; pharmaceutical form: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole (HOE239)
Description: Route of administration: oral; pharmaceutical form: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole (HOE239)
Description: Route of administration: oral; pharmaceutical form: tablet
Study: NCT06204913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group
Study: NCT05402111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
Description: PA will be prepared by the pharmacy staff according to the patient's prescribed treatment and will be orally administered. Multiple tablets or capsules may be required to achieve a single dose.
Study: NCT06204913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group
Study: NCT05833191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular vagus stimulation
Description: When the nervus tibialis approaches the medial malleolus, it approaches the surface. In this study, bilateral transcutaneous electrical nerve stimulation (TENS) electrodes will be placed under the medial malleolus approximately at the point where the tibialis nerve contacts the surface.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tibial Nerve Stimulation
Description: When the nervus tibialis approaches the medial malleolus, it approaches the surface. In this study, bilateral transcutaneous electrical nerve stimulation (TENS) electrodes will be placed under the medial malleolus approximately at the point where the tibialis nerve contacts the surface.
Study: NCT05953220

Intervention type: OTHER
Intervention: Exclusive tobacco smoking
Description: No intervention, participants own tobacco products

Intervention type: OTHER
Intervention: Exclusive e-cigarette use
Description: No intervention, participants own e-cigarette products

Intervention type: OTHER
Intervention: Dual use of e-cigarettes and tobacco smoking
Description: No intervention, participants own tobacco and e-cigarette products

Intervention type: OTHER
Intervention: No use of e-cigarettes or tobacco smoking
Description: No intervention
Study: NCT04661540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM4620-IE (Injectable Emulsion)
Description: Auxora is an injectable emulsion containing 1.6mg/ML of the active pharmaceutical ingredient CM4620. Auxora will be administered intravenously as a continuous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo is an injectable emulsion containing no active pharmaceutical ingredient. Placebo will be administered intravenously as a continuous infusion